The Medical Letter on Drugs and Therapeutics
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
The full article is available to subscribers Subscriber Login   

The FDA has approved reslizumab (Cinqair – Teva), a humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for add-on maintenance treatment of severe asthma in adults who have an eosinophilic phenotype. It is the second IL-5 antagonist to be approved in the US; mepolizumab (Nucala) was approved for the same indication in 2015.1

EOSINOPHILIC PHENOTYPE — What constitutes an eosinophilic phenotype is not well defined, but patients with this phenotype generally have severe disease with high eosinophil levels in blood and/or sputum despite treatment with a corticosteroid.2

OTHER MONOCLONAL ANTIBODIES — In clinical trials, mepolizumab reduced exacerbations and the need for maintenance oral corticosteroids in patients with severe asthma and high eosinophil counts. The recombinant humanized ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Reslizumab (Cinqair) for Severe Eosinophilic Asthma
Article code: 1497d
 Electronic, downloadable article - $25